Mr Shri Jagat Prakash Nadda  
Union Minister  
Ministry of Health & Family Welfare  
155 - A, Nirman Bhavan  
New Delhi - 110108  
India

22 March 2018

Dear Minister,

Re: Renewal of Pneumococcal Vaccine Support for India

We are writing in relation to the support that Gavi, the Vaccine Alliance, is providing to the Government of India for its Pneumococcal Vaccine (PCV) Programme.

Following Gavi’s review of the PCV Programme during its meeting of 6 February 2018, we are pleased to inform you that the PCV Programme support has been approved for the year 2018. The enclosed Decision Letter states the approved 2018 vaccine doses and indicative corresponding annual amount. The letter also states that Gavi committed $180 million for PCV support, out of a total of $500 million for the period 2016 – 2021, as provided under Annex 6 of the Partnership Framework Agreement (PFA).

As previously, we note that the Gavi Board’s decision to provide catalytic support for India’s PCV programme is subject to the provisions of Annex 6 of the PFA, in particular the commitments of the Government of India to fund additional costs required as well as scale-up of the programme, and to implement the programme as set out in the approved grant performance framework.

Please do not hesitate to contact the Senior Country Manager for India, Carol Szeto (cszeto@gavi.org), if you have any questions or concerns.

We remain at your disposal for any further enquiry.

Yours sincerely,

Hind Khatib-Othman  
Managing Director, Country Programmes
Cc:
PS, The Minister of Health and Family Welfare
PS, The Minister of Finance
Secretary, Ministry of Health and Family Welfare
Additional Secretary, MD NHM, Ministry of Health and Family Welfare
Joint Secretary, Ministry of Health and Family Welfare
Deputy Commissioner (UIP); MoHFW
Deputy Commissioner (UIP), MoHFW
WHO Country Representative
UNICEF Country Representative
WHO HQ
UNICEF Programme Division
UNICEF Supply Division
India Support for Pneumococcal Vaccine

This Decision Letter sets out the Programme Terms of a Programme.

**1. Country:** India

**2. Grant number:** 1719-IND-12d-X

**3. Date of Decision Letter:** 22 March 2018

**4. Date of the Partnership Framework Agreement:** 12 June 2015

**5. Programme title:** New Vaccine Support (NVS), Pneumococcal Routine

**6. Vaccine type:** Pneumococcal

**7. Requested product presentation and formulation of vaccine:** Pneumococcal (PCV13), 4 doses per vial, LIQUID

**8. Programme duration:** 2017 - 2019

**9. Programme Budget (indicative):** (subject to the terms of the Partnership Framework Agreement, if applicable)

<table>
<thead>
<tr>
<th></th>
<th>2017</th>
<th>2018</th>
<th>2019</th>
<th>Total²</th>
</tr>
</thead>
<tbody>
<tr>
<td>Programme</td>
<td>US$27,952,000</td>
<td>US$81,797,000</td>
<td>US$70,251,000</td>
<td>US$180,000,000</td>
</tr>
<tr>
<td>Budget (US$)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**10. Vaccine introduction grant (in US$):** Not applicable

**11. Indicative Annual Amounts:** (subject to the terms of the Partnership Framework Agreement)³

<table>
<thead>
<tr>
<th>Type of supplies to be purchased with Gavi funds in each year</th>
<th>2017</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of vaccines doses</td>
<td>8,916,000</td>
<td>26,657,800</td>
</tr>
<tr>
<td>Number of AD syringes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number of re-constitution syringes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number of safety boxes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Annual Amounts (US$)⁴</td>
<td>US$27,952,000</td>
<td>US$81,797,000</td>
</tr>
</tbody>
</table>

¹ This is the entire duration of the Programme.
² This is the total amount endorsed by Gavi for the entire duration of the Programme.
³ This is the amount that Gavi has approved.
⁴ The 2017 and 2018 amounts were estimated based on a price per dose of US$3.10 and US$3.05, respectively. Changes to the number of vaccine doses to be supported due to price changes will be reflected in the final year of support.
12. **Procurement agency:** UNICEF

13. **Self-procurement:** Not applicable

14. **Co-financing obligations:** Not applicable
   The Gavi co-financing policy does not apply to the current Gavi support for India as the country is not required to co-finance vaccines. Special arrangements apply as per Partnership Framework Agreement Annex 6.

15. **Operational support for campaigns:** Not applicable

16. **Additional reporting requirements:**

<table>
<thead>
<tr>
<th>Reports and other information</th>
<th>Due dates</th>
</tr>
</thead>
<tbody>
<tr>
<td>To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation, and vaccines received.</td>
<td>15 May 2018</td>
</tr>
<tr>
<td>In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.</td>
<td>To be agreed with Secretariat</td>
</tr>
</tbody>
</table>

17. **Financial clarifications:** Not applicable

18. **Other conditions:** Gavi’s catalytic support for India is subject to the provisions in Annex 6 of the Partnership Framework Agreement, and in particular:
   - The commitments of the Government of India to provide financing to fund the additional costs required for each programme that is funded with the Partnership Support and to scale up the programmes; and
   - Implementation of the programmes in line with the timelines, milestones and indicators set out in the performance framework.

Signed by,
**On behalf of Gavi**

Hind Khatib-Othman
Managing Director, Country Programmes
22 March 2018